- Home
- NG vs SNDX Comparison
NG vs SNDX Comparison
Compare NG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | SNDX |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NG | SNDX |
|---|---|---|
| Price | $10.18 | $21.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $10.17 | ★ $36.92 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 01-22-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $111,304,000.00 |
| Revenue This Year | N/A | $620.14 |
| Revenue Next Year | N/A | $115.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 595.65 |
| 52 Week Low | $2.26 | $8.58 |
| 52 Week High | $10.90 | $22.73 |
Technical Indicators
Market Signals| Indicator | NG | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 64.62 |
| Support Level | $9.78 | $19.72 |
| Resistance Level | $10.28 | $22.73 |
| Average True Range (ATR) | 0.41 | 0.91 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 83.73 | 59.94 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.